BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of investors of PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT) concerning the Company and its officers’ possible violations of federal securities laws. Injured investors are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights, and a potential class action lawsuit to recover investors’ losses.
On February 23, 2016, pre-market, PTC disclosed that the Company had received a Refuse to File letter from the United States Food and Drug Administration ("FDA") regarding PTC's New Drug Application for Translarna™ (ataluren), an oral, first-in-class, protein restoration therapy for the treatment of nonsense mutation Duchenne muscular dystrophy. The FDA contends in the Refuse to File letter that the application was partially incomplete, making the FDA’s substantive review of Translarna virtually impossible.
On this news, PTC stock has declined as much as $15.93, or 56.35%, to $15.93 per share during intra-day trading on February 23, 2016.
If you purchased PTC securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to email@example.com, or visit our website at http://www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.